The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Azacitidine maintance to improve DFS in elderly AML: HOVON-97 results
The HOVON-97 study (Netherlands Trial Registry NTR1810; EudraCT 2008-001290-15) investigated the use of azacitidine maintenance following intensive chemotherapy in older patients with acute myeloid leukemia (AML). We spoke to Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, about the recently published results. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
